{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-004613","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.200498+00:00","generated_at":"2026-06-19T14:33:20.220539+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Indaptus appoints Robert Martell, M.D., Ph.D. to Board of Directors","bullets":["Board size increased to nine; Martell appointed Class I director effective Feb 13, 2023.","Annual retainer of $50,000 for Board service; standard indemnification agreement.","Received initial option for 20,000 shares at $1.71/share (fair market value on grant date).","Annual equity award up to $75,000 value (Black-Scholes) vesting on first anniversary or upon change of control."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-004613","json":"https://secwatch.observer/filing/0001493152-23-004613.json","markdown":"https://secwatch.observer/filing/0001493152-23-004613.md","text":"https://secwatch.observer/filing/0001493152-23-004613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223004613/0001493152-23-004613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223004613/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T14:33:20.220539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a59f79299","claim":"Robert Martell was appointed as Class I director at Indaptus Therapeutics, Inc..","evidence_excerpt":"On February 13, 2023 (the “Effective Date”), the Board of Directors (the “Board”) of Indaptus Therapeutics, Inc. (the “Company”) increased its size to provide for a total of nine directors authorized to serve on the Board and appointed Robert Martell, M.D., Ph.D. as a Class I director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223004613/0001493152-23-004613-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}